Download Files:
Products Details
Product Description
– Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine (HY-12651A). Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria[1][2][3].
Web ID
– HY-106866
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C21H27N3O3
References
– [1]Noel S, et al. Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver. Basic Clin Pharmacol Toxicol. 2008 Dec;103(6):522-9.|[2]Dutta GP, et al. Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg. 1989 Dec;41(6):635-7.|[3]Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26(3):145-51.Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26(3):145-51.
CAS Number
– 79781-00-3
Molecular Weight
– 369.46
SMILES
– C/C(NCCCC(NC1=CC(OC)=CC2=C1N=CC=C2)C)=C3C(OCC/3)=O
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– Parasite
Isoform
– Plasmodium
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
